Streck announced on Monday that its MDx-Chex quality controls have received clearance from the US Food and Drug Administration.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel. The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.

Danaher on Tuesday announced that it will provide Cepheid's tuberculosis test to the Global Fund to Fight AIDS, TB, and Malaria, as well as to less-developed countries eligible for Cepheid's Global Access Program, at cost.

An expert panel led by researchers at the Ohio State University Wrexner Medical Center and College of Medicine has published a set of evidence-based guidelines for genetic testing and counseling for people with amyotrophic lateral sclerosis (ALS).

Natera on Thursday announced a new study within the Phase II I-SPY 2 trial that will evaluate the ability of its Signatera minimal residual disease test to monitor breast cancer patients' response to neoadjuvant therapy.

By studying cell-free DNA methylation (cfDNAme) patterns among pregnant women, researchers in Belgium have developed a liquid biopsy screening test to identify women at risk of early-onset preeclampsia (PE).

Wren Laboratories announced Thursday that it finalized a distribution agreement with Kindstar Globalgene Technology to distribute Wren's blood-based neuroendocrine tumor NETest throughout China.

ChromaCode on Thursday announced a partnership with cancer diagnostic laboratory Protean BioDiagnostics to launch a test for non-small cell lung cancer through an early access program.

Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company, announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca, a global biopharmaceutical company.

Next-generation sequencing data analysis platform company One Codex said on Thursday that it has formed a partnership with Swiss clinical product manufacturer 4bases to bring sample-to-report microbiome analysis solutions to clinicians in the EU.